Browse Studies — Arctuva

Phase 3

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the saf…

Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more

Estimated

~$10 – $8,750

ADARx Pharmaceuticals, Inc.NCT07428499

Phase 3

An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less Than 12 Years Old With Hereditary Angioedema

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HA…

Hereditary Angioedema (HAE)

Estimated

~$10 – $8,750

Ionis Pharmaceuticals, Inc.NCT07298447

Phase 3

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-releas…

Hereditary Angioedema (HAE)

Estimated

~$10 – $7,500

Pharvaris Netherlands B.V.NCT06679881

Phase 1

Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)

To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also a…

Hereditary Angioedema (HAE)AngioedemaBradykinin-mediated Angioedema+1 more

Estimated

~$10 – $7,500

Institute for Asthma and AllergyNCT07046806